๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Evolving end points for clinical trials in advanced colorectal cancer

โœ Scribed by Sharlene Gill; Daniel J. Sargent

Book ID
107535730
Publisher
Current Science Inc.
Year
2009
Tongue
English
Weight
251 KB
Volume
5
Category
Article
ISSN
1556-3790

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

Quantitative liver function tests as sur
Quantitative liver function tests as surrogate markers for end-points in controlled clinical trials: A retrospective feasibility study
โœ E Lotterer; J Hogel; W Gaus; W E Fleig; J Bircher ๐Ÿ“‚ Article ๐Ÿ“… 1997 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 215 KB

and nonabstinent patients with alcoholic liver disease investigated in this study, such numbers could serve for the planning Quantitative liver function tests such as the determination of controlled clinical trials, in which the control group is likely to deteriorate and the treated group is expecte

A phase III trial of 5-fluorouracil and
A phase III trial of 5-fluorouracil and leucovorin in the treatment of advanced colorectal cancer. A mayo clinic/north central cancer treatment group study
โœ Michael J. O'Connell ๐Ÿ“‚ Article ๐Ÿ“… 1989 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 498 KB ๐Ÿ‘ 2 views

The Mayo Clinic and the North Central Cancer Treatment Group (NCCTG) conducted a randomized clinical trial comparing five different combination chemotherapeutic regimens to single-agent 5-fluorouracil (5-FU), given by intravenous bolus technique (500 mg/m2 for 5 days) as a control, in the treatment